ReviewIndian journal of sexually transmitted diseases and AIDS
Antibiotic resistance in prevalent bacterial and protozoan sexually transmitted infections.
Review in Indian journal of sexually transmitted diseases and AIDS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Trial protocol: a parallel group, individually randomized clinical trial to evaluate the effect of a mobile phone application to improve sexual health among youth in Stockholm County.BMC public health · 2018Trial
- Review
- Insights into the Two Most Common Cancers of Primitive Gut-Derived Structures and Their Microbial Connections.Medicina (Kaunas, Lithuania) · 2024Review
- Sexually transmitted infections among active component members of the U.S. Armed Forces, 2015-2023.MSMR · 2024Article
- Impact of COVID-19 Pandemic on the Trends ofMicroorganisms · 2024Article
- Modeling the impact of changing sexual behaviors with opposite-sex partners and STI testing among women and men ages 15-44 on STI diagnosis rates in the United States 2012-2019.Infectious Disease Modelling · 2023Article
- Non-mucosal vaccination strategies to enhance mucosal immunity.Vaccine insights · 2023Article
- Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries.Frontiers in reproductive health · 2023Review
- The Impact of Genital Ulcers on HIV Transmission Has Been Underestimated-A Critical Review.Viruses · 2022Review
- Improved management can be achieved by introducing additional parameters in the syndromic diagnosis of nonviral sexually transmitted infections at low-resource settings.AJOG global reports · 2022Article
- Oxidative Stress, Testicular Inflammatory Pathways, and Male Reproduction.International journal of molecular sciences · 2021Review
- Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.Antimicrobial agents and chemotherapy · 2021Article
- The Natural Course ofMicroorganisms · 2021Article
- Multipurpose Prevention Technologies: Opportunities and Challenges to Ensure Advancement of the Most Promising MPTs.Frontiers in reproductive health · 2021Article
- Evaluation of peptide-rich root extracts of Calliandria portoriscensis (Jacq.) Benth (Mimosaceae) for in vitro antimicrobial activity and brine shrimp lethality.BMC complementary medicine and therapies · 2020Article
- [Sexually Transmitted Infections in the Tropics].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2018Article
- Evaluating the utility of syndromic case management for three sexually transmitted infections in women visiting hospitals in Delhi, India.Scientific reports · 2017Article
- Lycopene Inhibits Propagation of Chlamydia Infection.Scientifica · 2017Article
- Sexually transmitted infections: old foes on the rise.Microbial cell (Graz, Austria) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multi-drug resistant sexually transmitted infections (STIs) is causing a treatment crisis across the globe. While cephalosporin-resistant gonorrhea is one of the most pressing issues, extensively antibiotic resistant Chlamydia trachomatis and Mycoplasma hominis are also becoming commonplace. Experts have suggested that the failure of current treatment regimens are "largely inevitable" and have called for entirely new classes of antimicrobial agents. With the exception of several new classes of drugs primarily targeting nosocomial infections, progress has been slow. While pharmaceutical companies continue to introduce new drugs, they are based on decade-old discoveries. While there is disagreement about what constitutes new classes of antibiotics, many experts suggest that the last truly new family of antimicrobials was discovered in 1987. This review summarizes the existing literature on antibiotic resistance in common bacterial and protozoal STIs. It also briefly discusses several of the most promising alternatives to current therapies, and further examines how advances in drug delivery, formulation, concentration, and timing are improving the efficacy of existing treatments. Finally, the paper discusses the current state of pharmaceutical development for multidrug-resistant STI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.